Urinary epidermal growth factor excretion and breast cancer risk

Eur J Cancer Clin Oncol. 1988 Jun;24(6):1049-53. doi: 10.1016/0277-5379(88)90158-7.

Abstract

The amount of urinary epidermal growth factor (EGF) excreted was determined in 350 normal women of whom 37 subsequently developed breast cancer. These were a group of women selected on a case-control basis from 5000 volunteers who had participated in a prospective epidemiological study. Urinary EGF excretion was not correlated with known risk factors such as age at menarche or menopause, age at first or last full-term child or parity. Neither was it associated with day or length of menstrual cycle, breast mammographic parenchymal pattern or the blood concentration of prolactin, dehydroepiandrosterone or its sulphate ester. Univariate analysis indicated that the amount of urinary EGF was significantly correlated with urinary creatinine (P less than 0.001), age (P less than 0.001), urinary androsterone (P less than 0.02) or aetiocholanolone (P less than 0.02), height (P less than 0.05) and weight (P less than 0.05). However, multivariate analysis showed that the amount of urinary EGF was correlated only with creatinine excretion (P less than 0.001) and age (P less than 0.001) and that the significance of the other correlations were probably due to the confounding influence of creatinine.

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Androsterone / urine
  • Breast Neoplasms / urine*
  • Creatinine / urine
  • Epidermal Growth Factor / urine*
  • Etiocholanolone / urine
  • Female
  • Humans
  • Middle Aged
  • Risk Factors

Substances

  • Epidermal Growth Factor
  • Etiocholanolone
  • Creatinine
  • Androsterone